News Deal finally unlocks NHS access to ITF's Duchenne drug After nearly two years of wrangling, ITF's Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy.
News FDA okays Italfarmaco’s non-steroidal DMD therapy Duvyzat Italfarmaco’s oral HDAC inhibitor givinostat has been approved in the US as a treatment for Duchenne muscular dystrophy (DMD), becoming the first non-steroidal option for
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
